Compare Amylx Pharmaceuticals Inc (AMLX) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Sirius XM Holdings Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $22.57 (market cap $2.60B), while Sirius XM Holdings Inc trades at $27.99 (market cap $9.59B). The key difference: Sirius XM Holdings Inc is far larger — about 3.7× Amylx Pharmaceuticals Inc's market cap, and Sirius XM Holdings Inc pays a 3.8% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SIRI | |
|---|---|---|
Market Cap | $2.60B | $9.59B |
Sector | Health | Media |
52-Week High | $24.19 | $32.59 |
52-Week Low | $7.82 | $19.92 |
Enterprise Value | $2.36B | $18.87B |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, down 1.18% on the day, with strong analyst support (90.9% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum with moving averages supporting upward movement, though RSI levels indicate potential overbought conditions. Recent Q2 2026 earnings missed expectations with a loss of $0.39 per share, but the company maintains significant cash reserves through 2028 and anticipates key Phase 3 trial results for avexitide in late August/September 2026.
The investment case hinges on successful clinical trial outcomes and future revenue generation, with current negative profitability metrics offset by strong institutional backing and promising pipeline catalysts. Key risks include clinical trial failures, ongoing financial losses, and competitive pressures in the biotech sector.
Sirius XM Holdings (SIRI) trades at $27.99, down 1.82% on the day, with a bearish technical signal. The stock shows modest revenue growth of 1% in Q2 2026 but missed earnings estimates. Valuation metrics appear attractive with a P/E of 11.42 and P/B of 0.81. Recent news highlights its stable cash flow and potential in audio advertising, supported by Berkshire Hathaway's 37% stake.
The outlook is mixed; strong free cash flow and a dividend support income investors, but high debt and competitive pressures pose risks. Analyst consensus is bullish with a $33.17 price target, implying 18% upside. Key catalysts include continued subscriber retention and advertising growth, while execution missteps could hinder performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
